At the news
? NEUTRALIMPACT 6/10 424B5 filed Apr 15, 2026 at 17:25 ET
Revolution Medicines is raising $1.44 billion through a public offering of 10.56 million common shares at $142.00 per share, alongside a concurrent $500 million convertible note offering. The proceeds will fund R&D and general corporate purposes.
- Offering 10,563,381 shares of common stock at $142.00 per share, raising $1.44 billion in gross proceeds
- Concurrent offering of $500 million in 0.50% convertible senior notes due 2033
- Net proceeds estimated at $1.435 billion after underwriting discounts and expenses
- Proceeds to be used for R&D, potential commercialization, general corporate purposes, and possible acquisitions
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access